Maxim Group analyst Naz Rahman maintained a Hold rating on Cingulate Inc (CING – Research Report) yesterday. The company’s shares opened today at $1.05.
According to TipRanks, Rahman is an analyst with an average return of -3.8% and a 33.00% success rate. Rahman covers the Healthcare sector, focusing on stocks such as Viking Therapeutics, Palisade Bio, and Vertex Pharmaceuticals.
Currently, the analyst consensus on Cingulate Inc is a Moderate Buy with an average price target of $8.00.
The company has a one-year high of $23.79 and a one-year low of $1.00. Currently, Cingulate Inc has an average volume of 343.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cingulate Inc (CING) Company Description:
Cingulate Inc is a clinical stage biopharmaceutical company utilizing its proprietary precision timed release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes.
Read More on CING:
- Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update
- Cingulate reports Q4 EPS net loss $6.9M
- Cingulate to Participate in Benzinga All Live Access Event
- Cingulate to Attend DCAT Week 2024 in New York City
- CING Upcoming Earnings Report: What to Expect?
